Is BRIBF or NOBL a better dividend investment in 2026?

BRIBF currently yields 1062.70% with a 5% 5-year dividend growth rate. NOBL yields 2.17% with 5% growth. The better choice depends on your goal: BRIBF offers higher current income.

What is the dividend yield difference between BRIBF and NOBL?

BRIBF has a forward dividend yield of 1062.70% ($2.00/share annually). NOBL yields 2.17% ($2.27/share annually). The yield gap is 1060.53 percentage points.

Home › Compare › BRIBF vs NOBL

BRIBF vs NOBL: Dividend Comparison 2026

BRIBF yields 1062.70% · NOBL yields 2.17%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 BRIBF wins by $32084463.98M in total portfolio value

INVESTMENT

TIME HORIZON10 years

BRIBF

● Live price

1062.70%

Share price

$0.19

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$32084464.00M

Annual income

$27,073,008,093,454.87

Full BRIBF calculator →

NOBL

● Live price

2.17%

Share price

$104.67

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.9K

Annual income

$249.78

Full NOBL calculator →

Portfolio growth — BRIBF vs NOBL

📍 BRIBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BRIBF	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BRIBF + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BRIBF pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRIBF

Annual income on $10K today (after 15% tax)

$90,329.44/yr

After 10yr DRIP, annual income (after tax)

$23,012,056,879,436.64/yr

NOBL

Annual income on $10K today (after 15% tax)

$184.52/yr

After 10yr DRIP, annual income (after tax)

$212.31/yr

At 15% tax rate, BRIBF beats the other by $23,012,056,879,224.33/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRIBF + NOBL for your $10,000?

BRIBF: 50%NOBL: 50%

100% NOBL50/50100% BRIBF

Portfolio after 10yr

$16042232.01M

Annual income

$13,536,504,046,852.32/yr

Blended yield

84.38%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRIBF buys

NOBL buys

No recent congressional trades found for BRIBF or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBRIBFNOBL

Forward yield	1062.70% ✓	2.17%
Annual dividend / share	$2.00	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$32084464.00M ✓	$22.9K
Annual income after 10y	$27,073,008,093,454.87 ✓	$249.78
Total dividends collected	$31704729.30M ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: BRIBF vs NOBL ($10,000, DRIP)

Year	BRIBF Portfolio	BRIBF Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$116,970	$106,269.93	$10,917	$217.08	+$106.1K → BRIBF
2	$1,286,876	$1,161,718.25	$11,903	$221.48	+$1.27M → BRIBF
3	$13,321,776	$11,944,818.28	$12,962	$225.68	+$13.31M → BRIBF
4	$129,817,926	$115,563,625.92	$14,099	$229.68	+$129.80M → BRIBF
5	$1,191,375,681	$1,052,470,500.56	$15,319	$233.49	+$1191.36M → BRIBF
6	$10,301,704,979	$9,026,933,000.21	$16,628	$237.10	+$10301.69M → BRIBF
7	$83,971,400,363	$72,948,576,035.34	$18,033	$240.53	+$83971.38M → BRIBF
8	$645,568,504,677	$555,719,106,288.88	$19,539	$243.78	+$645568.49M → BRIBF
9	$4,683,603,649,023	$3,992,845,349,018.69	$21,154	$246.86	+$4683603.63M → BRIBF
10	$32,084,463,997,910	$27,073,008,093,454.87	$22,884	$249.78	+$32084463.98M → BRIBF

BRIBF vs NOBL: Complete Analysis 2026

BRIBF — Stock

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

Full BRIBF Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this BRIBF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRIBF vs SCHD BRIBF vs JEPI BRIBF vs O BRIBF vs KO BRIBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.